research Increased Expression of TSPEAR in Colorectal Cancer Predicts Poor Prognosis
High TSPEAR levels in colorectal cancer predict worse outcomes.
Search
for
Sort by
Research
450-480 / 1000+ results 
research Recovery of resistant alopecia areata treated with tofacitinib: An 8-year-old child's case report
Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.
research Oral Tofacitinib for the Management of Moderate to Severe Alopecia Areata in Children and Adolescents: A Retrospective Study of 36 Patients
Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.
research Response of alopecia areata of the beard to oral tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
research Treatment of resistant alopecia areata with tofacitinib
Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
research 572 Development of immunotherapies targeting TCR-Vβ2 for treatment of cutaneous T cell lymphoma
Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
research Pyrene Excimer Nucleic Acid Probes for Biomolecule Signaling
Pyrene excimer nucleic acid probes are promising for detecting biomolecules accurately with potential for biological research and drug screening.
research Tofacitinib in the Recalcitrant Cases of Alopecia Areata: A Pilot Study
Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
research Characterization of LHTric-1, a new monospecific monoclonal antibody to the trichocyte keratin Ha1
LHTric-1 is a specific antibody useful for studying hair and nail formation.
research Adalimumab improves health-related quality of life (HRQoL) in patients with moderate to severe hidradenitis suppurativa (HS): Results from the first 12 weeks of PIONEER II
Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.
research Prescription Pattern of Tofacitinib for Alopecia Areata Among the Dermatologists in Saudi Arabia: A Cross-Sectional Study
Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.
research Real-World Effectiveness of JAK Inhibitors for Alopecia Totalis and Alopecia Universalis: A Single-Center Experience
JAK inhibitors are effective and safe for treating severe alopecia areata.
research Angiogenic effects of recombinant thymosin β4 in a mouse hindlimb ischemia model
Recombinant thymosin β4 promotes blood vessel growth and reduces muscle damage.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research Increased Expression of TSPEAR in Colorectal Cancer Predicts Poor Prognosis
High TSPEAR levels in colorectal cancer predict worse outcomes.
research Nanostructured lipid carriers promote percutaneous absorption and hair follicle targeting of tofacitinib for treating alopecia areata
Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
research Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes
A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
research Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study
Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
research Ultrasound-Assisted Facile Synthesis and Anticancer Evaluation of Novel N-(2-substituted phenyl-4-oxathiazolidine-3-carbonothioyl) benzamide
Researchers made new compounds that could potentially be developed into anticancer drugs.
research Novel ALK5 inhibitor TP0427736 reduces TGF-β induced growth inhibition in human outer root sheath cells and elongates anagen phase in mouse hair follicles
TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.
research Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
research Toll-like receptor 4 (TLR4): new insight immune and aging
TLR4 is important in aging-related diseases and could be a new treatment target.
research Biomedical engineering approaches for the delivery of JAGGED1 as a potential tissue regenerative therapy
JAGGED1 could help regenerate tissues for bone loss and heart damage if delivered correctly.
research YAP/TAZ Signalling Controls Epidermal Keratinocyte Fate
YAP and TAZ proteins control skin cell growth and repair.
research Drug–DrugCoamorphous System of Tadalafil andFinasteride for Enhanced Pharmaceutical Performance
A new combination of tadalafil and finasteride improves drug performance and stability.
research Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
research 874 Mesothelioma of the Tunica Vaginalis Testis: A Clinicopathologic Study of 14 Patients with Evaluation of Markers of Mesothelial Malignancy
Mesothelioma of the tunica vaginalis testis is rare, often high-grade, and has a median survival of about 24 months.
research Influence of Different Designs of High-Heeled Shoes on Kinematics, Kinetics, and Muscle EMG of Female Gait
Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
research Gas-propelled anti-hair follicle aging microneedle patch for the treatment of androgenetic alopecia
A new microneedle patch helps treat hair loss by improving drug delivery to hair follicles.
research 267 Single- and multiple-ascending dose studies of DS-2325a, a KLK5 inhibitor for the treatment of Netherton syndrome
DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.